Insider Selling: Keryx Biopharmaceuticals, Inc. (KERX) CFO Sells $15,569.46 in Stock
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) CFO Scott A. Holmes sold 2,582 shares of Keryx Biopharmaceuticals stock in a transaction on Monday, October 30th. The shares were sold at an average price of $6.03, for a total transaction of $15,569.46. The sale was disclosed in a document filed with the SEC, which is available through this link.
Several institutional investors and hedge funds have recently bought and sold shares of KERX. State Street Corp boosted its stake in shares of Keryx Biopharmaceuticals by 20.1% in the 1st quarter. State Street Corp now owns 3,479,370 shares of the biopharmaceutical company’s stock valued at $21,432,000 after purchasing an additional 582,624 shares in the last quarter. Monarch Partners Asset Management LLC acquired a new stake in shares of Keryx Biopharmaceuticals in the 2nd quarter valued at approximately $3,059,000. Chicago Equity Partners LLC acquired a new stake in shares of Keryx Biopharmaceuticals in the 2nd quarter valued at approximately $2,756,000. Vanguard Group Inc. boosted its stake in shares of Keryx Biopharmaceuticals by 5.1% in the 2nd quarter. Vanguard Group Inc. now owns 7,198,269 shares of the biopharmaceutical company’s stock valued at $52,043,000 after purchasing an additional 349,521 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in Keryx Biopharmaceuticals by 24.3% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,666,934 shares of the biopharmaceutical company’s stock worth $12,052,000 after buying an additional 326,285 shares during the period. Institutional investors own 65.20% of the company’s stock.
KERX has been the subject of a number of research reports. Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 8th. Morgan Stanley reissued an “equal weight” rating and set a $7.00 target price (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. BidaskClub lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. ValuEngine raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, Maxim Group set a $9.00 target price on shares of Keryx Biopharmaceuticals and gave the company a “buy” rating in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $7.48.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.